PM
AVTX icon

Prosight Management’s Avalo Therapeutics AVTX Stock Holding History

Prosight Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-40
Closed -$665K – 41
2019
Q1 		$665K Sell
40
-67
-63% -$1M 0.29% 35
2018
Q4 		$994K Buy
+107
New +$1.19M 0.51% 31

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Prosight Management's AVTX Position: Q2 2019 in Review

Prosight Management sold out of Avalo Therapeutics (AVTX) in Q2 2019, closing a stake of 40 shares — an estimated $665K sold.

Prosight Management first reported a position in AVTX in Q4 2018 and held it in 2 quarters. The position peaked at $994K in Q4 2018. 36 funds tracked by Wall St. Rank hold AVTX as of Q2 2019.

  • Prosight Management reported no remaining Avalo Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Prosight Management sold 40 Avalo Therapeutics shares in Q2 2019, an estimated $665K.
  • Prosight Management first reported a position in Avalo Therapeutics in Q4 2018 and held it in 2 quarters.
  • Prosight Management's Avalo Therapeutics position peaked at $994K in Q4 2018.
  • 36 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2019.

Based on Prosight Management's 13F filing for Q2 2019, filed 14 Aug 2019.